Microbiome Function in Atopic Dermatitis

微生物组在特应性皮炎中的功能

• 批准号: 10611881
• 负责人: Richard L Gallo
• 金额: $ 47.25万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10611881
• 关键词: 18 year old; 6 year old; Adult; Age; Anti-Inflammatory Agents; Antibiotic Resistance; Antibiotics; Antigen-Presenting Cells; Atopic Dermatitis; Bacteria; Cells; Characteristics; Child; Childhood; Chronic; Chronic Disease; Clinical Research; Cutaneous; Defect; Dermal; Dermis; Development; Disease; Dose; Elements; Environment; Epithelial Cells; Frequencies; Functional disorder; Goals; Growth; Human; Immune Targeting; Immune response; Immune system; Immunosuppression; Immunosuppressive Agents; Immunotherapy; Incidence; Inflammation; Inflammatory; Innovative Therapy; Interruption; Intervention; Lymphocyte; Measures; Microbe; Mission; Mupirocin; Myelogenous; Nature; Oral; Patients; Penetration; Peptide Hydrolases; Peptides; Phenotype; Play; Population; Recurrence; Research; Severities; Shapes; Skin; Staphylococcus aureus; Staphylococcus hominis; Surface; Testing; Topical Antibiotic; Topical application; Toxin; Triamcinolone; Work; antimicrobial; beneficial microorganism; cohort; dysbiosis; fighting; improved; innovation; insight; keratinocyte; mast cell; member; microbial; microbiome; microbiome therapeutics; novel therapeutic intervention; pediatric patients; prototype; response; side effect; skin barrier; skin disorder; skin microbiome; success

Summary/Abstract Atopic dermatitis (AD) is a common inflammatory skin disease. Recent observations strongly suggest that the abnormal microbiome present on the skin of subjects with AD is a major factor that influences the severity and chronic nature of this disorder. In particular, Staphylococcus aureus promotes epidermal barrier dysfunction and exacerbates the local and systemic immune response. In healthy subjects, beneficial members of the skin microbiome act to limit the growth of Staphylococcus aureus but these beneficial bacterial strains are missing on adults with AD. This project seeks to understand why adults with AD lack beneficial bacterial strains by study of the survival of a prototype strain of Staphylococcus hominis on AD skin. Interventions to improve its survival will be tested, and application in the pediatric AD population will be evaluated. Overall, successful completion of the proposed aims of this ADRN Clinical Research Center will advance understanding of AD and provide essential information to permit development of an innovative new therapeutic approach based on targeted microbiome therapy.

摘要/文摘